OncoVantaHealthPrecision Oncology
Back to store
Inluriyo (imlunestrant)Rx Only

Form

capsules

Strength

100 mg

Pack

30 capsules

Breast Cancer

Inluriyo

imlunestrant · 100 mg

Efficacy Gauge · Clinical Signal

Target Engagement92%
Progression-Free Survival78%
Tolerability Profile84%

Mechanism of Action

Imlunestrant is an oral selective estrogen receptor degrader that drives complete degradation of the estrogen receptor, shutting down the ER signaling axis that fuels ER-positive tumor growth, including in tumors with ESR1 mutations.

Manufacturer

OncoVantaHealth

Target Protein

ER

Delivery

Tablets

Quantity

30 capsules

Critical Safety Information

Inluriyo is a prescription therapy. It may interact with CYP3A4 inhibitors and hormonal treatments. Do not co-administer with grapefruit. Report pregnancy or nursing status immediately. Requires ongoing hepatic monitoring.

Pricing Tier · Select Quantity

Total

$2,650

All orders require a valid prescription and clinical review before fulfillment. Final pricing confirmed after verification.

Patient Reviews

Write a Review

Share your experience with this therapy.

No reviews yet. Be the first to share your experience.

OncoVantaHealth

A clinical-grade command center for life-extending oncology therapies. Precision access, transparent pricing, and scientifically vetted care.

Rx Only · Prescription Therapies

Affiliated with Princess Margaret Cancer Centre · UHN

Support

This storefront provides access to prescription oncology therapies. All orders require a valid prescription and clinical review. Not a substitute for medical advice.